133 related articles for article (PubMed ID: 16912201)
1. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers.
Deans AJ; Khanna KK; McNees CJ; Mercurio C; Heierhorst J; McArthur GA
Cancer Res; 2006 Aug; 66(16):8219-26. PubMed ID: 16912201
[TBL] [Abstract][Full Text] [Related]
2. Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.
Wang H; Zeng ZC; Bui TA; DiBiase SJ; Qin W; Xia F; Powell SN; Iliakis G
Cancer Res; 2001 Jan; 61(1):270-7. PubMed ID: 11196174
[TBL] [Abstract][Full Text] [Related]
3. RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors.
Martin RW; Orelli BJ; Yamazoe M; Minn AJ; Takeda S; Bishop DK
Cancer Res; 2007 Oct; 67(20):9658-65. PubMed ID: 17942895
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Maggiorella L; Deutsch E; Frascogna V; Chavaudra N; Jeanson L; Milliat F; Eschwege F; Bourhis J
Cancer Res; 2003 May; 63(10):2513-7. PubMed ID: 12750274
[TBL] [Abstract][Full Text] [Related]
5. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints.
Xie G; Habbersett RC; Jia Y; Peterson SR; Lehnert BE; Bradbury EM; D'Anna JA
Oncogene; 1998 Feb; 16(6):721-36. PubMed ID: 9488036
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining.
Zhuang J; Zhang J; Willers H; Wang H; Chung JH; van Gent DC; Hallahan DE; Powell SN; Xia F
Cancer Res; 2006 Feb; 66(3):1401-8. PubMed ID: 16452195
[TBL] [Abstract][Full Text] [Related]
7. Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining.
Wang HC; Chou WC; Shieh SY; Shen CY
Cancer Res; 2006 Feb; 66(3):1391-400. PubMed ID: 16452194
[TBL] [Abstract][Full Text] [Related]
8. CDK2 Is Required for the DNA Damage Response During Porcine Early Embryonic Development.
Wang H; Kim NH
Biol Reprod; 2016 Aug; 95(2):31. PubMed ID: 27307074
[TBL] [Abstract][Full Text] [Related]
9. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1.
Bau DT; Fu YP; Chen ST; Cheng TC; Yu JC; Wu PE; Shen CY
Cancer Res; 2004 Jul; 64(14):5013-9. PubMed ID: 15256476
[TBL] [Abstract][Full Text] [Related]
11. Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.
Vella S; Tavanti E; Hattinger CM; Fanelli M; Versteeg R; Koster J; Picci P; Serra M
PLoS One; 2016; 11(11):e0166233. PubMed ID: 27898692
[TBL] [Abstract][Full Text] [Related]
12. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage.
Huang H; Regan KM; Lou Z; Chen J; Tindall DJ
Science; 2006 Oct; 314(5797):294-7. PubMed ID: 17038621
[TBL] [Abstract][Full Text] [Related]
13. Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts.
Zhong Q; Boyer TG; Chen PL; Lee WH
Cancer Res; 2002 Jul; 62(14):3966-70. PubMed ID: 12124328
[TBL] [Abstract][Full Text] [Related]
14. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
[TBL] [Abstract][Full Text] [Related]
15. The role of the BRCA1 tumor suppressor in DNA double-strand break repair.
Zhang J; Powell SN
Mol Cancer Res; 2005 Oct; 3(10):531-9. PubMed ID: 16254187
[TBL] [Abstract][Full Text] [Related]
16. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.
Mukhopadhyay UK; Senderowicz AM; Ferbeyre G
Cancer Res; 2005 Apr; 65(7):2872-81. PubMed ID: 15805289
[TBL] [Abstract][Full Text] [Related]
17. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
18. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.
Chen MC; Zhou B; Zhang K; Yuan YC; Un F; Hu S; Chou CM; Chen CH; Wu J; Wang Y; Liu X; Smith DL; Li H; Liu Z; Warden CD; Su L; Malkas LH; Chung YM; Hu MC; Yen Y
Mol Pharmacol; 2015 Jun; 87(6):996-1005. PubMed ID: 25814515
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
Paculová H; Kramara J; Šimečková Š; Fedr R; Souček K; Hylse O; Paruch K; Svoboda M; Mistrík M; Kohoutek J
Tumour Biol; 2017 Oct; 39(10):1010428317727479. PubMed ID: 29025359
[TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest.
Yun J; Zhong Q; Kwak JY; Lee WH
Oncogene; 2005 Jun; 24(25):4009-16. PubMed ID: 15782115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
